Unlocked Labs

What Unlocked Labs does

Unlocked Labs Inc., founded in 2020 and headquartered in Laramie, Wyoming, is a privately held biotechnology company that develops medical foods powered by proprietary, patent-pending active postbiotic ingredients (APIs). The company's platform centers on enzyme-rich bacterial husks — derived from optimized probiotic bacteria — that are designed to break down specific disease-driving compounds in the gastrointestinal tract. Its lead product, StoneShield, is a medical food intended for the dietary management of kidney stone risk; it is powered by OX164, an enzyme-rich postbiotic containing oxalate decarboxylase that converts dietary oxalate into formate in the stomach, before absorption. StoneShield is formulated with cranberry extract, magnesium citrate, and vitamin B for additional urinary tract support.

The business model is direct-to-consumer medical food sales, leveraging a Medical Food + GRAS regulatory pathway to enable capital-efficient development without prescription requirements. Target customer segments are individuals at risk for calcium oxalate kidney stones (~11% of the global population, with oxalate found in roughly 80% of all kidney stones) and individuals with excessive cholesterol levels (also ~11% global prevalence), the latter representing the company's pipeline expansion beyond the lead product. Unlocked Labs has raised approximately $4.93M across 13 disclosed rounds from July 2020 through December 2024, including non-dilutive NIH and NSF federal grants (~$2.44M), venture capital from Astanor Ventures and SOSV/IndieBio, state funding from the Wyoming Business Council, and angel capital. Strategic R&D collaborations include Lund University, the University of Wyoming, and Charles River Laboratories for preclinical work. The company is currently scaling production and anticipates commercial launch of StoneShield in 2026.

Name

Unlocked Labs

Legal name

Unlocked Labs Inc.

Website

https://unlocked.bio

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Unlocked Labs is a pre-revenue biotechnology company developing medical foods powered by proprietary active postbiotic enzymes. Its lead product StoneShield targets kidney stone risk by breaking down dietary oxalate in the stomach using the patented OX164 enzyme ingredient.

Ownership category

akta.pro rank

Product category

Medical Foods

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Probiotics, Prebiotics & Postbiotics (Direct-Fed Microbials) (AFADALAE)

Keywords

• Medical foods
• Postbiotic ingredients
• Kidney stone prevention
• Microbial enzyme technology
• Dietary management

Headquarters

HQ city

Laramie

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Medical Food Sales: Revenue will be generated through sales of medical food products like StoneShield, targeting consumers affected by kidney stones and other chronic conditions. Product not yet launched as of April 2026.
2. Pipeline Product Revenue: Additional active postbiotic ingredients in pipeline targeting specific compounds involved in chronic conditions, including products for excessive cholesterol levels.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

Unlocked Labs develops medical foods powered by proprietary, patent-pending active postbiotic ingredients (APIs) — enzyme-rich bacterial husks made from optimized probiotic bacteria. Its lead product, StoneShield, is formulated with the OX164 postbiotic ingredient (containing oxalate decarboxylase enzyme) along with cranberry extract, magnesium citrate, and vitamin B, and is intended for the dietary management of kidney stone risk by breaking down dietary oxalate in the stomach before absorption.

Product overview

Unlocked Labs develops medical foods powered by proprietary, patent-pending active postbiotic ingredients (APIs) - enzyme-rich bacterial husks derived from optimized probiotic bacteria. Their lead product is StoneShield (for kidney stone risk management, powered by OX164 enzyme), with a development pipeline targeting other chronic conditions including excessive cholesterol levels. The company combines advanced microbial enzyme science, food-grade manufacturing, and efficient regulatory pathways (Medical food + GRAS) to create targeted medical foods that are safe, scalable, and clinically relevant.

Differentiator

Problem solved

Functional benefit

Brands

• StoneShield: Lead medical food product intended for dietary management of kidney stone risk. Powered by OX164 enzyme and formulated with cranberry extract, magnesium citrate, and vitamin B for urinary tract health support.
• OX164
• Unlocked Medical Foods

Products and services

• StoneShield Lead medical food product intended for the dietary management of kidney stone risk; powered by the OX164 active postbiotic ingredient and formulated with cranberry extract, magnesium citrate, and vitamin B for additional urinary tract support. Designed to be taken with meals to break down dietary oxalate in the stomach before absorption, intended for use under physician supervision.

Quantifiable outcome

• Oxalate is found in about 80% of kidney stones, making it the number 1 kidney stone causing compound
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered supporting.

• University of WyomingsupportingStrategic or Co-development PartnerResearch collaboration providing access to unique equipment, facilities and resources for pre-clinical studies.
• Charles River LaboratoriessupportingStrategic or Co-development PartnerCollaborative research partner providing access to specialized laboratory facilities and resources for pre-clinical studies.
• Lund UniversitysupportingStrategic or Co-development PartnerSwedish research institution collaborating with Unlocked on preclinical studies. Prof. Stefan Pierzynowski and Dr. Kateryna Pierzynowska from Lund help design and execute preclinical trials.

Scale indicators3 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• BioGaia: Swedish probiotics company that develops and commercializes probiotic and postbiotic products for human health, including GI and metabolic indications. Comparable to Unlocked because both leverage defined microbial/postbiotic mechanisms for targeted health outcomes sold through consumer and healthcare channels.

Broad incumbents

• Novonesis (formerly Chr. Hansen): Global bioscience company and one of the largest suppliers of probiotic and postbiotic ingredients for food, dietary supplements, and animal nutrition. Comparable to Unlocked as a source of postbiotic ingredient technology and a potential manufacturing partner or competitor in enzyme-based consumer health products.
• Nestlé Health Science: Global medical nutrition business that develops and markets medical foods for conditions ranging from kidney disease to rare metabolic disorders. Comparable to Unlocked as a broad incumbent in the same Medical Food regulatory category that Unlocked is entering with its kidney stone product.
• Danone Nutricia: Specialized nutrition arm of Danone producing medical foods and clinical nutrition products for metabolic and GI conditions. Comparable to Unlocked as a large, established medical foods manufacturer with regulatory, manufacturing, and distribution capabilities that Unlocked would need to match.
• Yakult Honsha: Japanese multinational that pioneered consumer probiotic dairy products based on defined Lactobacillus strains with documented health claims. Comparable to Unlocked because both commercialize defined microbial products with specific health positioning aimed at broad consumer populations.

Emerging players

• Synlogic: Clinical-stage synthetic biology company developing engineered microbial therapies for metabolic and immunological diseases, including an oxalate-targeting program (SYNB8802). Comparable to Unlocked as both pursue engineered/postbiotic microbial approaches to break down disease-driving compounds in the GI tract.
• Vedanta Biosciences: Clinical-stage company developing defined bacterial consortia (live biotherapeutic products) for immune-mediated diseases. Comparable to Unlocked because both translate microbiome and microbial enzyme science into precision, defined-product therapeutics for chronic conditions.
• Seres Therapeutics: Clinical-stage microbiome therapeutics company developing defined bacterial consortia (e.g., VOWST, approved for recurrent C. difficile). Comparable to Unlocked as both pursue defined microbiome-based products for chronic and metabolic conditions, though Seres focuses on prescription biologics.

Others

• Abbott Nutrition: Division of Abbott that produces medical foods and nutritional products (e.g., Pediasure, Ensure, Oxepa) for clinical and consumer use. Comparable to Unlocked as a large incumbent operating in the Medical Food category that Unlocked is targeting with StoneShield.
• International Flavors & Fragrances (IFF) Health & Biosciences: Global ingredient company producing probiotics, enzymes, and postbiotics for the food, dietary supplement, and animal nutrition industries (including the legacy DuPont Nutrition & Biosciences portfolio). Comparable to Unlocked as a potential ingredient supplier, contract manufacturing partner, or competitive threat through its probiotic/enzyme product portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/unlocked.labs
• LinkedInlinkedin.com/company/unlocked-bio
• Xx.com/unlocked_labs

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds14 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Unlocked Labs